BNP Paribas Arbitrage SA lifted its holdings in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) by 71.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 35,323 shares of the biotechnology company’s stock after acquiring an additional 14,758 shares during the quarter. BNP Paribas Arbitrage SA owned 0.05% of Progenics Pharmaceuticals worth $260,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Piedmont Investment Advisors LLC acquired a new stake in shares of Progenics Pharmaceuticals in the second quarter worth $103,000. Numeric Investors LLC acquired a new stake in shares of Progenics Pharmaceuticals in the second quarter worth $2,877,000. Royce & Associates LP increased its stake in shares of Progenics Pharmaceuticals by 7.7% in the second quarter. Royce & Associates LP now owns 1,346,374 shares of the biotechnology company’s stock worth $9,142,000 after acquiring an additional 95,700 shares during the period. New York State Common Retirement Fund increased its stake in shares of Progenics Pharmaceuticals by 11.0% in the second quarter. New York State Common Retirement Fund now owns 239,525 shares of the biotechnology company’s stock worth $1,626,000 after acquiring an additional 23,723 shares during the period. Finally, Principal Financial Group Inc. increased its stake in shares of Progenics Pharmaceuticals by 8.7% in the second quarter. Principal Financial Group Inc. now owns 594,849 shares of the biotechnology company’s stock worth $4,039,000 after acquiring an additional 47,647 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.

A number of analysts have recently weighed in on PGNX shares. ValuEngine lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, October 6th. Zacks Investment Research lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Cantor Fitzgerald restated a “buy” rating and set a $15.00 price target on shares of Progenics Pharmaceuticals in a research report on Wednesday, September 27th. Aegis restated a “buy” rating and set a $14.00 price target on shares of Progenics Pharmaceuticals in a research report on Tuesday, August 22nd. Finally, Needham & Company LLC restated a “strong-buy” rating and set a $14.00 price target on shares of Progenics Pharmaceuticals in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $13.75.

Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) opened at $6.12 on Thursday. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.86 and a quick ratio of 7.86. Progenics Pharmaceuticals Inc. has a 52-week low of $4.60 and a 52-week high of $11.72.

Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. The company had revenue of $2.70 million for the quarter, compared to analyst estimates of $3.58 million. Progenics Pharmaceuticals had a negative net margin of 445.81% and a negative return on equity of 67.61%. The firm’s revenue was down 95.0% on a year-over-year basis. During the same quarter last year, the business earned $0.52 earnings per share. equities analysts forecast that Progenics Pharmaceuticals Inc. will post -0.92 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “BNP Paribas Arbitrage SA Grows Stake in Progenics Pharmaceuticals Inc. (PGNX)” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/bnp-paribas-arbitrage-sa-grows-stake-in-progenics-pharmaceuticals-inc-pgnx/1762945.html.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.